DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $718 | -38.6% | 2,894 | -40.6% | 0.03% | -36.4% |
| Q2 2023 | $1,169 | -1.9% | 4,870 | +3.0% | 0.04% | -12.0% |
| Q1 2023 | $1,192 | -6.4% | 4,728 | -1.4% | 0.05% | -12.3% |
| Q4 2022 | $1,273 | -99.9% | 4,797 | +0.7% | 0.06% | -8.1% |
| Q3 2022 | $1,231,000 | +1.2% | 4,765 | -0.8% | 0.06% | +5.1% |
| Q2 2022 | $1,217,000 | +22.9% | 4,802 | +42.2% | 0.06% | +34.1% |
| Q1 2022 | $990,000 | +5.7% | 3,376 | +18.5% | 0.04% | +4.8% |
| Q4 2021 | $937,000 | +7.5% | 2,848 | -0.6% | 0.04% | -4.5% |
| Q3 2021 | $872,000 | +12.1% | 2,864 | -1.2% | 0.04% | +10.0% |
| Q2 2021 | $778,000 | +90.2% | 2,898 | +59.6% | 0.04% | +81.8% |
| Q1 2021 | $409,000 | +16.5% | 1,816 | +14.9% | 0.02% | +4.8% |
| Q4 2020 | $351,000 | -15.2% | 1,581 | -17.7% | 0.02% | -25.0% |
| Q3 2020 | $414,000 | +5.6% | 1,921 | -13.4% | 0.03% | 0.0% |
| Q2 2020 | $392,000 | +111.9% | 2,218 | +65.6% | 0.03% | +75.0% |
| Q1 2020 | $185,000 | -11.5% | 1,339 | -1.6% | 0.02% | +6.7% |
| Q4 2019 | $209,000 | -1.4% | 1,361 | -7.4% | 0.02% | -11.8% |
| Q3 2019 | $212,000 | +1.9% | 1,470 | +1.0% | 0.02% | 0.0% |
| Q2 2019 | $208,000 | +20.2% | 1,456 | +11.1% | 0.02% | +6.2% |
| Q1 2019 | $173,000 | +28.1% | 1,310 | 0.0% | 0.02% | +14.3% |
| Q4 2018 | $135,000 | -4.9% | 1,310 | 0.0% | 0.01% | +7.7% |
| Q3 2018 | $142,000 | +14.5% | 1,310 | +4.5% | 0.01% | +8.3% |
| Q2 2018 | $124,000 | +0.8% | 1,253 | 0.0% | 0.01% | -7.7% |
| Q1 2018 | $123,000 | +0.8% | 1,253 | -4.5% | 0.01% | 0.0% |
| Q4 2017 | $122,000 | +2.5% | 1,312 | -5.1% | 0.01% | -7.1% |
| Q3 2017 | $119,000 | +1.7% | 1,383 | 0.0% | 0.01% | -6.7% |
| Q2 2017 | $117,000 | -10.0% | 1,383 | -9.0% | 0.02% | -21.1% |
| Q1 2017 | $130,000 | -13.9% | 1,520 | -21.6% | 0.02% | -24.0% |
| Q4 2016 | $151,000 | +46.6% | 1,940 | +48.2% | 0.02% | +38.9% |
| Q3 2016 | $103,000 | +68.9% | 1,309 | +115.7% | 0.02% | +50.0% |
| Q2 2016 | $61,000 | +5.2% | 607 | 0.0% | 0.01% | 0.0% |
| Q1 2016 | $58,000 | -29.3% | 607 | -31.3% | 0.01% | -33.3% |
| Q4 2015 | $82,000 | +9.3% | 883 | +0.1% | 0.02% | +12.5% |
| Q3 2015 | $75,000 | -56.9% | 882 | -56.6% | 0.02% | -54.3% |
| Q2 2015 | $174,000 | +2.4% | 2,031 | +1.4% | 0.04% | -2.8% |
| Q1 2015 | $170,000 | +102.4% | 2,003 | +105.0% | 0.04% | +89.5% |
| Q4 2014 | $84,000 | +13.5% | 977 | 0.0% | 0.02% | +5.6% |
| Q3 2014 | $74,000 | -3.9% | 977 | 0.0% | 0.02% | -10.0% |
| Q2 2014 | $77,000 | +5.5% | 977 | 0.0% | 0.02% | 0.0% |
| Q1 2014 | $73,000 | +180.8% | 977 | +194.3% | 0.02% | +122.2% |
| Q4 2013 | $26,000 | +13.0% | 332 | 0.0% | 0.01% | 0.0% |
| Q3 2013 | $23,000 | +9.5% | 332 | 0.0% | 0.01% | +12.5% |
| Q2 2013 | $21,000 | – | 332 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |